IP Library › Granted Patent US 11,530,262
Granted Patent B2
US 11,530,262 · App. 16/256,223 · Granted Dec 20, 2022

Interleukin-31 monoclonal antibodies for veterinary use

Inventors: Gary Francis Bammert (Portage, MI); Steven Alan Dunham (Kalamazoo, MI); Sebastian C. J. Steiniger (Kalamazoo, MI)
Assignee: Zoetis Services LLC
C07K16/244A61P17/00A61P35/00A61P37/00G01N33/6869A61K2039/505A61K2039/552C07K2317/24C07K2317/33C07K2317/34C07K2317/76C07K2317/92G01N2333/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,530,262
App. No.
16/256,223
Granted
Dec 20, 2022
Kind
B2
Abstract

A monoclonal antibody, or antigen-binding portion thereof is provided that specifically binds to a region on a mammalian IL-31 protein involved with interaction of the IL-31 protein with its co-receptor, wherein the binding of said antibody to said region is impacted by mutations in a 15H05 epitope binding region selected from: a region between about amino acid residues 124 and 135 of a feline IL-31 sequence represented by SEQ ID NO: 157 (Feline_IL31_wildtype); a region between about amino acid residues 124 and 135 of a canine IL-31 sequence represented by SEQ ID NO: 155 (Canine_IL31); and a region between about amino acid residues 118 and 129 of an equine IL-31 sequence represented by SEQ ID NO: 165 (Equine_IL31). Such antibodies can be in the form of veterinary compositions useful for treating IL-31-mediated disorders in cats, dogs, or horses.

Claims (27)

1. A composition comprising an anti-IL31 antibody, wherein said antibody comprises:

(1) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 13, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO:14, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 15, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 16, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 17, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO:18;

(2) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 19, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 20, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 21, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 22, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 23, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 24;

(3) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 25, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 27, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 28, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 29, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 30;

(4) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 31, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 32, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 33, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 34, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 35, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 36;

(5) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 37, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 38, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 39, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 40, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 41, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 42;

(6) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 43, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 44, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 45, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 46, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 47, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48;

(7) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 49, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 50, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 51, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 52, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 53, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 54;

(8) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 55, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 56, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 57, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 58, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 59, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 60;

(9) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 61, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 62, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 63, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 64, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 65, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 66);

(10) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 200, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 201, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 202, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 203, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 204, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 205; or

(11) a VH-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 206, a VH-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 207, a VH-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 208, a VL-CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 209, a VL-CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 210, and a VL-CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 211.

2. The composition of claim 1 , wherein the antibody comprises:

(1) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 77 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 75;

(2) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 81 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 79;

(3) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 85 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 83;

(4) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 89 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 87;

(5) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 93 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 91;

(6) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 97 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 95;

(7) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 101 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 99;

(8) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 105 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 103;

(9) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 109 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 107;

(10) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 214 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 212; or

(11) a VL chain comprising the amino acid sequence set forth in SEQ ID NO: 218 and a VH chain comprising the amino acid sequence set forth in SEQ ID NO: 216.

3. The composition of claim 1 , wherein the antibody is a chimeric antibody.

4. The composition of claim 1 , wherein the antibody is caninized, felinized, or equinized.

5. A composition comprising a therapeutically effective amount of the antibody of claim 1 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: BAMMERT, GARY FRANCIS; DUNHAM, STEVEN ALAN; STEINIGER, SEBASTIAN C. J.
To: ZOETIS SERVICES LLC
Reel/Frame 048729/0492 →
Continuity (2)
Provisional Application 62643940 · Mar 16, 2018
Related Publication 20190284272A1 · Sep 19, 2019